Welcome to our dedicated page for Catheter Precision SEC filings (Ticker: VTAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Catheter Precision, Inc. (VTAK) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10‑K, 10‑Q and 8‑K, along with proxy statements and registration statements. As a NYSE American–listed medical device company focused on the cardiac electrophysiology market, Catheter Precision uses these filings to report on its business, financial condition, capital structure, and material events affecting VTAK stock.
Through its periodic reports, such as the annual Form 10‑K and quarterly Forms 10‑Q, Catheter Precision presents audited and interim financial statements, management’s discussion and analysis, and detailed risk factor sections. These documents expand on topics referenced in press releases, including the company’s history of operating losses, its need for additional financing to continue as a going concern, regulatory dependencies for its VIVO and LockeT products, and competitive and operational risks.
Current reports on Form 8‑K capture specific developments, such as reverse stock split implementation, amendments to short‑term promissory notes held by related parties, termination of an at‑the‑market equity offering program, and the release of quarterly financial results. Other 8‑K filings incorporate legal opinions related to registration statements and announcements about regulatory approvals in certain markets.
Definitive proxy statements on Schedule 14A outline matters submitted to stockholders, including proposals to authorize reverse stock splits, increase authorized shares, approve share issuances under NYSE American rules, and ratify the appointment of independent registered public accounting firms. These documents also describe the mechanics of virtual stockholder meetings and voting procedures.
On Stock Titan, AI-powered tools summarize lengthy filings so readers can quickly understand key points from Catheter Precision’s 10‑K, 10‑Q, and 8‑K reports without reading every page. Real-time updates from EDGAR ensure new filings appear promptly, while specialized views highlight items relevant to equity structure changes, financing arrangements, and governance decisions. Users can also review insider-related information disclosed in filings, such as amendments to notes held by executives and affiliated entities, to better understand relationships between management and the company’s capital structure.
Catheter Precision, Inc. (VTAK) reported that it furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The company provided this update under Item 2.02 of the Exchange Act.
The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under Section 18. VTAK’s common stock trades on NYSE American.
Catheter Precision, Inc. reported Q3 2025 results showing small but growing sales and ongoing losses, alongside a going concern warning. Revenue was
Cash and cash equivalents were
To fund operations, the company completed a private placement on
Catheter Precision (VTAK) reported the results of a stockholder Special Meeting held on October 10, 2025. Of the 1,487,266 shares outstanding as of September 10, 2025 (the record date), 641,616 shares were represented in person or by proxy, constituting approximately 43.1% of shares entitled to vote.
Stockholders considered three proposals. Reported vote totals were: Proposal 1 — 497,162 for, 133,882 against, 10,571 abstentions; Proposal 2 — 610,134 for, 16,778 against, 14,703 abstentions; Proposal 3 — 514,362 for, 120,394 against, 6,860 abstentions.
Catheter Precision, Inc. is calling a special stockholder meeting on October 10, 2025 to vote on three items. The main proposal would amend its charter to increase authorized common shares from 60,000,000 to 500,000,000, giving the company room to issue large amounts of stock or stock-linked securities in future financings. The company states it will be unable to fund operations and pay obligations beyond January 2026 unless a financing is completed.
Stockholders are also being asked to ratify WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2026, and to approve the ability to adjourn the meeting if there are not enough votes for the other proposals. The proxy describes a complex capital structure, including Series X and Series B preferred stock and 1,078,895 outstanding warrants with various exercise prices, ownership limits, and change‑of‑control protections.
Catheter Precision, Inc. is asking stockholders at an October 10, 2025 virtual special meeting to approve a major increase in authorized common stock, from 60,000,000 to 500,000,000 shares. The company currently has 1,487,266 common shares outstanding as of September 10, 2025.
The board explains that it needs far more authorized shares to pursue additional financings to fund ongoing operations, stating it will be unable to fund operations and pay obligations beyond January 2026 unless a financing is completed. The proxy also asks stockholders to ratify WithumSmith+Brown, PC as auditor for 2026 and to approve a proposal allowing adjournment of the meeting if needed to secure sufficient votes.
Catheter Precision filed an 8-K to attach a legal opinion supporting its Form S-3 prospectus supplement and to announce that its LockeT surgical vessel closing device received regulatory approval in Great Britain. The press release highlights potential benefits of LockeT for patient comfort, faster recovery and increased clinical throughput, but also contains extensive forward-looking cautionary language. The company discloses material weaknesses in internal control, a history of losses, the need to raise additional funds to continue operations, and multiple operational and market risks including competition, reimbursement, supply-chain and regulatory challenges.
Catheter Precision, Inc. implemented a 1-for-19 reverse stock split of its common stock after stockholder authorization, effective at 12:01 a.m. ET on August 15, 2025. The company combined every 19 issued shares into one share and reduced issued and outstanding common shares from approximately 23,327,516 to approximately 1,227,764. The common stock continues to trade under the symbol VTAK on the NYSE American on a split-adjusted basis and received a new CUSIP number.
Authorized capital remains unchanged at 10 million preferred and 60 million common shares. Proportionate adjustments were made to outstanding stock options, warrants, conversion prices and shares available under incentive plans. Fractional shares will not be issued; holders entitled to fractions will receive cash pro rata from aggregated fractional-share sales, net of customary fees.
Armistice Capital, LLC and Steven Boyd report collective beneficial ownership of 1,120,635 shares of Catheter Precision, Inc. common stock, representing 4.99% of the class. The filing states the Reporting Persons hold shared voting and dispositive power over these shares and have no sole voting or dispositive power. Armistice is the investment manager of the Master Fund, which directly holds the shares, and the Master Fund disclaims beneficial ownership by virtue of the investment management agreement. The Reporting Persons certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control.
James Joseph Caruso, a director of Catheter Precision, Inc. (VTAK), reported an option award on 08/12/2025. The filing shows an acquisition of 50,000 stock options with an exercise price of $0.18. The options are exercisable beginning 08/12/2025 and reference an 08/12/2035 date in the derivative table, with the filing stating the options vest one-third per year beginning on the first anniversary of the grant. After this transaction Caruso beneficially owns the 50,000 underlying shares directly. The form is signed 08/14/2025.
Catheter Precision, Inc. (VTAK) reported an insider transaction in which a company director was granted 50,000 stock options with an exercise price of $0.18. The options were granted on the reported transaction date and vest one-third each year beginning on the first anniversary of the grant. The options are exercisable through the expiration date in 2035, and the reporting person holds 50,000 underlying shares post-transaction.
This disclosure is a routine director equity award that creates long-term option-based compensation and the right to acquire 50,000 shares at the stated strike price subject to the vesting schedule.
FAQ
What is the current stock price of Catheter Precision (VTAK)?
What is the market cap of Catheter Precision (VTAK)?
